GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (ASX:ACR) » Definitions » Cash And Cash Equivalents
中文

Acrux (ASX:ACR) Cash And Cash Equivalents

: A$4.57 Mil (As of Dec. 2023)
View and export this data going back to 2004. Start your Free Trial

Acrux's quarterly cash and cash equivalents increased from Dec. 2022 (A$4.35 Mil) to Jun. 2023 (A$6.23 Mil) but then stayed the same from Jun. 2023 (A$6.23 Mil) to Dec. 2023 (A$4.57 Mil).

Acrux's annual cash and cash equivalents declined from Jun. 2021 (A$15.27 Mil) to Jun. 2022 (A$5.83 Mil) but then increased from Jun. 2022 (A$5.83 Mil) to Jun. 2023 (A$6.23 Mil).


Acrux Cash And Cash Equivalents Historical Data

The historical data trend for Acrux's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrux Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.15 9.21 15.27 5.83 6.23

Acrux Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.60 5.83 4.35 6.23 4.57

Acrux Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Acrux  (ASX:ACR) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Acrux Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Acrux's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Acrux (ASX:ACR) Business Description

Industry
Traded in Other Exchanges
Address
103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.